These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2373670)

  • 21. In vitro activity of two beta-lactam antibiotics against strains of the Bacteroides fragilis group isolated from humans and from Callithrix penicillata marmosets.
    Avila-Campos MJ; de Carvalho MA; Veiga-Damasceno CA; Osório-Cisalpino E
    Rev Latinoam Microbiol; 1994; 36(3):159-62. PubMed ID: 7709091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotics of choice against Bacteroides fragilis.
    Bittner J; Voinescu V; Munteanu V; Antohi M; Ardeleanu J
    Arch Roum Pathol Exp Microbiol; 1982; 41(3):213-8. PubMed ID: 7159211
    [No Abstract]   [Full Text] [Related]  

  • 24. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility.
    Piddock LJ; Wise R
    J Antimicrob Chemother; 1987 Feb; 19(2):161-70. PubMed ID: 3571041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.
    Andrew JH; Greenwood D
    J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteroides fragilis and HR 756.
    Wise R
    J Antimicrob Chemother; 1979 Jan; 5(1):115-6. PubMed ID: 762000
    [No Abstract]   [Full Text] [Related]  

  • 28. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Activity of seven antimicrobial agents against "Bacteroides fragilis" (author's transl)].
    Tytgat F
    Ann Microbiol (Paris); 1980; 131(1):39-44. PubMed ID: 6899739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.
    Pumbwe L; Chang A; Smith RL; Wexler HM
    J Antimicrob Chemother; 2006 Sep; 58(3):543-8. PubMed ID: 16840432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of fluoroquinolone resistance in Bacteroides fragilis accompanied by resistance to beta-lactam antibiotics.
    Kato N; Miyauchi M; Muto Y; Watanabe K; Ueno K
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1437-8. PubMed ID: 2848446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacteroides fragilis group: trends in resistance.
    Fille M; Mango M; Lechner M; Schaumann R
    Curr Microbiol; 2006 Feb; 52(2):153-7. PubMed ID: 16450067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-beta-lactamase mediated cefoxitin resistance.
    Wexler HM; Halebian S
    J Antimicrob Chemother; 1990 Jul; 26(1):7-20. PubMed ID: 2211448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The changing pattern of antibiotic susceptibilities of Bacteroides fragilis in Kuwait.
    Elhag KM; Mustafa AK; Pazhoor AA
    J Antimicrob Chemother; 1989 Nov; 24(5):699-707. PubMed ID: 2599994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin.
    Brogan O; Garnett PA; Brown R
    J Antimicrob Chemother; 1989 Apr; 23(4):660-2. PubMed ID: 2745269
    [No Abstract]   [Full Text] [Related]  

  • 36. The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom.
    Fox AR; Phillips I
    J Antimicrob Chemother; 1987 Oct; 20(4):477-88. PubMed ID: 3680088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of ceftizoxime against Bacteroides fragilis: comparison with benzylpenicillin, cephalothin, and cefoxitin.
    Eley A; Greenwood D
    Antimicrob Agents Chemother; 1981 Sep; 20(3):332-5. PubMed ID: 6272629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antibacterial activity of cefotetan against Bacteroides fragilis group clinical isolates.
    Menozzi M; Avanzini P; Lecchini R; Bigi M; Chezzi C
    Chemioterapia; 1987 Jun; 6(2 Suppl):88-91. PubMed ID: 3509541
    [No Abstract]   [Full Text] [Related]  

  • 39. The contribution of beta-lactamases to beta-lactam resistance in Bacteroides fragilis.
    Simpson IN; Page CD; Harper PB
    J Antimicrob Chemother; 1982 Jan; 9(1):29-45. PubMed ID: 6977524
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased resistance to cefoxitin and cefotetan among Bacteroides fragilis isolates from abdominal sources in patients undergoing surgery.
    Ehrenkranz NJ; Alfonso B
    Clin Infect Dis; 1993 Dec; 17(6):1080-2. PubMed ID: 8110948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.